Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q8IVG5
UPID:
SAM9L_HUMAN
Alternative names:
-
Alternative UPACC:
Q8IVG5; A0JP23; A0JP24; A0PJG8; A4D1G8; D6W5Q6; Q2TV71; Q2TV75; Q2UZV8; Q8IWI4; Q8N3L9; Q8N875
Background:
Sterile alpha motif domain-containing protein 9-like (SAMD9L) plays a crucial role in cellular processes, including endosome fusion and the down-regulation of growth factor signaling through the internalization of growth factor receptors. This protein's involvement in these pathways underscores its importance in cellular homeostasis and signal transduction.
Therapeutic significance:
SAMD9L is implicated in several genetic disorders, such as Ataxia-pancytopenia syndrome, Monosomy 7 myelodysplasia and leukemia syndrome 1, and Spinocerebellar ataxia 49. These associations highlight the protein's potential as a target for therapeutic intervention in these diseases, offering hope for novel treatment strategies.